Injectable Drug Delivery Market Valued to be USD 320 Million in 2020 and will grow USD 560 Million by 2027 at a CAGR value of 10.2% during the forecast period.

Injectable drug delivery is a route of administration of the drug through the intravenous route to relief the patient complications, this route is mostly adopted during an emergency as it is the most effective way of delivering the drug. The injectable delivery raises the bioavailability of the drug at the systemic circulation, which provides the availability of the drug at the desired site of action. The market of injectable drug delivery is expected to gain traction on the account of advancement in technology.

The global injectable drug delivery market size was valued at US$ 15,939.0 million in 2017, and is expected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026).

Rising prevalence of chronic disorder such as anaphylaxis and diabetes is projected to foster the market growth of the injectable drug delivery

Rising prevalence of chronic diseases such as diabetes and other diseases is projected to fuel market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to the World Health Organization (WHO) 2018 factsheet, around 8.5% of adults aged 18 years and above had diabetes in 2014 globally.

Request for Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-sample/2768

Moreover, the market players are focused on product development and the launch of injectors, which is also projected to foster the growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for a generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received FDA approval.

On the other hand, growing product recalls is projected to hamper market growth. In December 2012, Bracco Diagnostics Inc., initiated a Class I recall of nine lots of Isovue Pre-Filled Power Injector Syringes, which are to be used with Stellant CT Injection Systems, due to presence of visible particles in syringes observed at the end of standard stability studies on retained samples, according to the U.S. Food and Drug Administration (FDA)

Growing product approval and launch of new product in the North America region is projected to bolster the market growth

North America holds a dominant position in the global injectable drug delivery market, and this can be attributed to the rising focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

Moreover, the growing incidence of chronic diseases such as diabetes, anaphylaxis, and cardiac arrest in the region is projected to propel the growth of the market over the forecast period. For instance, according to the Journal of Allergy and Clinical Immunology, 2014, the prevalence of anaphylaxis in the U.S. was 1.6% in the general population, while the number of hospitalizations associated with the disease is ever-increasing in the U.S.

Get Flat USD 2000 OFF

Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2768

Reasons to Purchase this Report:

Current and future of global Injectable Drug Delivery Market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

In addition, growing initiatives by major players to produce auto-injectors available to patients suffering from anaphylaxis is further projected to boost the global injectable drug delivery market. For instance, Mylan N.V. provides discount cards to epinephrine buyers and offers discounts up to US$ 300 on the branded version of EpiPen and up to US$ 25 on the approved generic version of EpiPen.

Key Players

Major players operating in the global injectable drug delivery market include Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, and Injex Pharma GmbH

Contact US:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: [email protected]

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

The post Injectable Drug Delivery Market Valued to be USD 320 Million in 2020 and will grow USD 560 Million by 2027 at a CAGR value of 10.2% during the forecast period. appeared first on Gatorledger.

Injectable drug delivery is a route of administration of the drug through the intravenous route to relief the patient complications, this route is mostly adopted during an emergency as it is the most effective way of delivering the drug. The injectable delivery raises the bioavailability of the drug at the systemic circulation, which provides the availability of the drug at the desired site of action. The market of injectable drug delivery is expected to gain traction on the account of advancement in technology.

The global injectable drug delivery market size was valued at US$ 15,939.0 million in 2017, and is expected to exhibit a CAGR of 8.3% over the forecast period (2018 – 2026).

Rising prevalence of chronic disorder such as anaphylaxis and diabetes is projected to foster the market growth of the injectable drug delivery

Rising prevalence of chronic diseases such as diabetes and other diseases is projected to fuel market growth. According to the World Health Organization (WHO), in November 2011, around 60 million people in Europe suffered from diabetes, of which around 10.3% were men and 9.6% were women aged 25 years and above. Similarly, according to the World Health Organization (WHO) 2018 factsheet, around 8.5% of adults aged 18 years and above had diabetes in 2014 globally.

Request for Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-sample/2768

Moreover, the market players are focused on product development and the launch of injectors, which is also projected to foster the growth of the global injectable drug delivery market over the forecast period. For instance, in 2016, Berlin-Chemie launched BerliPen areo 3 in Germany. BerliPen areo 3 is a 300 unit insulin pen, which can be used with six different insulins in the treatment of type 1 and 2 diabetes. Similarly, in August 2018, Teva Pharmaceuticals received the U.S. Food and Drug Administration (FDA) approval for a generic version of Mylan’s EpiPen and EpiPen Jr. Teva Pharmaceuticals is the first generic manufacturer that received FDA approval.

On the other hand, growing product recalls is projected to hamper market growth. In December 2012, Bracco Diagnostics Inc., initiated a Class I recall of nine lots of Isovue Pre-Filled Power Injector Syringes, which are to be used with Stellant CT Injection Systems, due to presence of visible particles in syringes observed at the end of standard stability studies on retained samples, according to the U.S. Food and Drug Administration (FDA)

Growing product approval and launch of new product in the North America region is projected to bolster the market growth

North America holds a dominant position in the global injectable drug delivery market, and this can be attributed to the rising focus of regional players in research and development and product launches. In 2017, Bayer received U.S. Food and Drug Administration (FDA) approval for a connected auto-injector-BETACONNECT for relapsing-remitting multiple sclerosis medication and companion app- myBETAapp. The app allows patients to automatically have a record of all their injections and share that record with their nurse or physician. Similarly, in October 2018, Genentech announced the U.S. Food and Drug Administration (FDA) approval for single-dose prefilled syringes (PFS) for Xolair (omalizumab) as an additional formulation for both allergic asthma and chronic idiopathic urticaria (CIU) indications.

Moreover, the growing incidence of chronic diseases such as diabetes, anaphylaxis, and cardiac arrest in the region is projected to propel the growth of the market over the forecast period. For instance, according to the Journal of Allergy and Clinical Immunology, 2014, the prevalence of anaphylaxis in the U.S. was 1.6% in the general population, while the number of hospitalizations associated with the disease is ever-increasing in the U.S.

Get Flat USD 2000 OFF

Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2768

Reasons to Purchase this Report:

Current and future of global Injectable Drug Delivery Market outlook in the developed and emerging markets

The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.

Regions/countries that are expected to witness the fastest growth rates during the forecast period.

The latest developments, market shares, and strategies that are employed by the major market players.

In addition, growing initiatives by major players to produce auto-injectors available to patients suffering from anaphylaxis is further projected to boost the global injectable drug delivery market. For instance, Mylan N.V. provides discount cards to epinephrine buyers and offers discounts up to US$ 300 on the branded version of EpiPen and up to US$ 25 on the approved generic version of EpiPen.

Key Players

Major players operating in the global injectable drug delivery market include Becton, Dickinson and Company, Pfizer Inc., Novo Nordisk A/S, Gerresheimer AG, Carl-Zeiss-Stiftung, Terumo Corporation, Vetter Pharma-Fertigung GmbH & Co. KG, SHL Group, Owen Mumford Limited, and Injex Pharma GmbH

Contact US:

Coherent Market Insights

1001 4th Ave, #3200 Seattle, WA 98154, U.S.

Email: [email protected]

United States of America: +1-206-701-6702

United Kingdom: +44-020-8133-4027

Japan: +050-5539-1737

India: +91-848-285-0837

The post Injectable Drug Delivery Market Valued to be USD 320 Million in 2020 and will grow USD 560 Million by 2027 at a CAGR value of 10.2% during the forecast period. appeared first on Gatorledger.